Evidence map›Paper›PMID 39695327›Full record

ArticleGene therapy2025

AAV library screening identifies novel vector for efficient transduction of human aorta.

Lena C Schröder, Leonard Hüttermann, Anca Kliesow Remes, Jakob C Voran, Susanne Hille, Wiebke Sommer, Georg Lutter, Gregor Warnecke, Derk Frank, Dennis Schade and 1 more

Abstract read
In one paragraph

Article in Gene therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Tissue-specific gene delivery approaches.Bioengineering & translational medicine · 2026
    Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Lena C SchröderDepartment of Internal Medicine V, University of Kiel, Kiel, Germany.
Leonard HüttermannDepartment of Internal Medicine V, University of Kiel, Kiel, Germany.ORCID 0000-0002-6357-3418
Anca Kliesow RemesDepartment of Internal Medicine V, University of Kiel, Kiel, Germany.
Jakob C VoranGerman Centre for Cardiovascular Research, Partner Site Hamburg/Kiel/Lübeck, Kiel, Germany.ORCID 0009-0000-4547-9260
Susanne HilleDepartment of Internal Medicine V, University of Kiel, Kiel, Germany.ORCID 0000-0002-9809-4636
Wiebke SommerGerman Centre for Cardiovascular Research, Partner Site Hamburg/Kiel/Lübeck, Kiel, Germany.
Georg LutterGerman Centre for Cardiovascular Research, Partner Site Hamburg/Kiel/Lübeck, Kiel, Germany.
Gregor WarneckeGerman Centre for Cardiovascular Research, Partner Site Hamburg/Kiel/Lübeck, Kiel, Germany.
Derk FrankGerman Centre for Cardiovascular Research, Partner Site Hamburg/Kiel/Lübeck, Kiel, Germany.
Dennis SchadeGerman Centre for Cardiovascular Research, Partner Site Hamburg/Kiel/Lübeck, Kiel, Germany.
Oliver J MüllerDepartment of Internal Medicine V, University of Kiel, Kiel, Germany. oliver.mueller@uksh.de.ORCID 0000-0001-8223-2638

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Targeted gene delivery to vascular smooth muscle cells (VSMCs) could prevent or improve a variety of diseases affecting the vasculature and particularly the aorta. Thus, we aimed to develop a delivery vector that efficiently targets VSMCs. We selected engineered adeno-associated virus (AAV) capsids from a random AAV capsid library and tested the top enriched motifs in parallel screening through individual barcoding. This approach allowed us to distinguish capsids that only transduce cells based on genomic DNA (gDNA) from those also mediating transgene expression based on transcribed cDNA reads. After three rounds of selection on primary murine VSMCs (mVSMCs), we identified a novel targeting motif (RFTEKPA) that significantly improved transduction and gene expression efficiency over AAV9-wild type (WT) and increased expression in mVSMCs by 70% compared to the previously identified SLRSPPS peptide. Further analysis showed that the novel motif also improved expression in human aortic smooth muscle cells (HAoSMCs) and human aortic tissue ex vivo up to threefold compared to SLRSPPS and approximately 70-fold to AAV9-WT. This high cross-species transduction efficiency makes the novel capsid motif a potential candidate for future clinical application in vascular diseases.

Indexed as

AortaDependovirusGenetic VectorsTransduction, GeneticAnimalsCapsid ProteinsCells, CulturedGene LibraryGenetic TherapyHumansMiceMuscle, Smooth, VascularMyocytes, Smooth MuscleCapsid Proteins

Identifiers

PMID39695327
PMCPMC11946879

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.